Related Experiment Video
Updated: May 21, 2026
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma
1Medical Oncology, Magna Græcia University, Viale Europa, Campus Salvatore Venuta, 88100 Catanzaro, Italy. tassone@unicz.it
Abstract:
Mouse models of multiple myeloma (MM) are basic tools for translational research and play a fundamental role in the development of new therapeutics against plasma cell malignancies. All available models, including transplantable murine tumors in syngenic mice, xenografts of established human cell lines in immunocompromised mice and transgenic models that mirror specific steps of MM pathogenesis, have demonstrated some weaknesses in predicting clinical results, particularly for new drugs targeting the human bone marrow microenvironment (huBMM). The recent interest to models recapitulating the in vivo growth of primary MM cells in a human (SCID-hu) or humanized (SCID-synth-hu) host recipient has provided powerful platforms for the investigation of new compounds targeting MM and/or its huBMM. Here, we review and discuss strengths and weaknesses of the key in vivo models that are currently utilized in the MM preclinical investigation.
Insights
Mouse models are crucial for developing multiple myeloma (MM) treatments. Newer models using humanized hosts show promise for testing drugs targeting MM and the human bone marrow microenvironment (huBMM).
Area of Science:
- Oncology
- Hematology
- Translational Research
Background:
- Mouse models are essential for multiple myeloma (MM) research and therapeutic development.
- Current models like syngeneic tumors, xenografts, and transgenic systems have limitations in predicting clinical outcomes, especially for drugs targeting the human bone marrow microenvironment (huBMM).
Purpose of the Study:
- To review and discuss the strengths and weaknesses of key in vivo models used in preclinical multiple myeloma research.
- To highlight the potential of humanized host models for investigating novel MM therapeutics.
Main Methods:
- Review of existing literature on various mouse models for multiple myeloma.
- Comparative analysis of transplantable murine tumors, xenografts, transgenic models, and SCID-hu/SCID-synth-hu models.
- Discussion of model limitations concerning the human bone marrow microenvironment (huBMM).
Main Results:
- Established mouse models have inherent limitations in accurately predicting clinical efficacy for MM therapies.
- Models utilizing primary MM cells in humanized hosts (SCID-hu, SCID-synth-hu) offer improved platforms for evaluating drugs targeting MM and the huBMM.
Conclusions:
- No single mouse model perfectly predicts clinical responses in multiple myeloma.
- Humanized mouse models represent a significant advancement for preclinical MM drug development, particularly for therapies targeting the complex huBMM.
More Related Videos
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
07:17A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease
Published on: January 29, 2021
Related Concept Videos
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...